Shalby Limited — Q2 FY27 — November 4, 2026

1. Overall Tone of Management: Cautious

Management stresses broad-based hospital growth, Medtech’s improving operations and expected cost savings. But the underlying results are less robust than the framing: consolidated revenue rose 9.8% year on year while EBITDA was nearly flat, and EBITDA margin fell to 14.6% from 15.9%. Several profit improvements depend on future efficiency and supply-chain benefits. Q&A also exposed persistent concerns about Medtech’s cumulative losses, delayed expansion and the limited visibility of forward targets.

2. Key Themes from Management Commentary

Hospitals: broader specialty mix and better utilization. Joint replacement remains the flagship, while nephrology, urology, oncology, general surgery and critical care are growing faster. Occupancy improved to 52% (55% excluding Gurgaon), and ALOS shortened to 3.58 days.
Hospital margins remain under pressure, with savings expected later. Management cited first-half efficiencies in outsourced manpower and expects materials and consumables initiatives to benefit the P&L from Q3.
Shalby International/Gurgaon is improving, but not yet at cash break-even. Revenue rose about 50% year on year to approximately ₹30 crore and the unit was EBITDA-positive. Cash break-even is expected near the end of Q4.
Medtech is moving from turnaround toward growth, but profitability is still developing. It recorded a fifth consecutive quarter of positive EBITDA. Management is expanding surgeon engagement and geography, while shifting supply chain to reduce cost of goods.
Capital allocation is being tilted toward hospitals. Management said 80–90% of additional internal accruals will go to hospital investment. With major investments largely made, it expects lower capex and eventual debt reduction.
Clinical capability and quality infrastructure. Management highlighted robotic surgery, transplant programs, diagnostic upgrades and clinical standardization across the network.

3. Q&A Analysis

A. Medtech’s losses, strategic rationale and capital allocation

Analysts asked: Why continue the implant business after substantial subsidiary losses, rather than focus solely on hospitals? What is the growth, profitability and debt roadmap?
Management responded: The implant opportunity remains attractive, but manufacturing cost is the key constraint. It said unit manufacturing cost has fallen to less than half of its acquisition-era level and could decline another 30–40% with the new supply chain. It expects the business to become self-sustaining soon and said most fresh capital will go to hospitals.
Assessment: Management defended the strategic rationale but did not provide the requested medium-term revenue, EBITDA or debt figures: “I am unable to give you numbers.” The emphasis on directing future capital to hospitals is a meaningful response to investor concern.

B. Medtech margins, supply chain and inventory

Analysts asked: What will drive profitability and when will supply-chain changes translate into better margins? How will inventory and debt improve?
Management responded: Operational efficiencies are already appearing; the new supply chain is expected to benefit the P&L from Q4 FY27, with a full-quarter impact from Q1 FY28. Inventory days were reported at 784, versus about 1,200 a year earlier. Management expects further debt reduction, but declined to quantify it.
Assessment: The timing is more specific than the profit targets, but the core margin improvement remains prospective. The transcript gives different inventory comparisons in different answers; the stated 784-day figure is the clearest current-period number.

C. Oncology price caps and regulatory exposure

Analysts asked: Would the new cap on oncology drug prices hurt hospital margins? Could similar caps affect Medtech?
Management responded: It expects an insignificant impact because its margins are already around the government’s expected range and many surgeries are package-based. It said no consumables cap was under discussion and expected an NPPA implant-price revision to support revenue.
Assessment: The answer was confident, but based on a “high-level analysis”; management did not quantify the exposure.

D. Hospital growth, expansion and capex

Analysts asked: What are the expansion plans, including Gurgaon and Mumbai? What is the FOCO strategy and expected capex?
Management responded: It expects to add beds at Gurgaon using available FSI, with beds operational in 12–18 months. Mumbai expansion remains delayed pending approvals and alignment with trustees. FOCO activity will be selective and limited to profitable facilities. FY27 capex is expected to remain around replacement levels; H1 capex was about ₹10 crore.
Assessment: Gurgaon plans were relatively concrete; Mumbai had “no update” despite the project’s continued presence in earlier calls. Management explicitly rejected an aggressive FOCO strategy.

E. FY27 financial outlook, tax and debt

Analysts asked: What are the revenue, margin and tax expectations?
Management responded: FY27 top-line growth is expected to be double digit. EBITDA margin should be better than the previous year and improve further in the next financial year. ETR is expected to be about 45%. Debt is expected to decline in coming quarters, but no debt target was given.
Assessment: Revenue and tax guidance were numerical; margin guidance remained directional. The debt outlook is confident but unquantified.

4. Guidance / Outlook

Quantitative guidance

FY27 revenue: Double-digit growth.
FY27 ETR: Approximately 45%.
Capex: H1 FY27 was about ₹10 crore; H2 is expected to be similar, largely replacement capex.
Gurgaon/Shalby International: Cash break-even expected around the end of Q4; management also indicated an additional 20–30% growth from current levels would bring the unit to PBT-neutrality.
Gurgaon beds: Additional beds expected to be operational in 12–18 months.

Qualitative signals

Consolidated EBITDA margin is expected to improve versus FY26 and improve further in the next financial year; no specific FY27 margin target was provided.
Hospital materials and consumables savings are expected to begin flowing through from Q3.
Medtech supply-chain savings are expected from Q4 FY27, with full-quarter impact in Q1 FY28.
Management expects continued debt reduction as Medtech cash requirements fall and capex remains low.
Approximately 80–90% of additional internal accruals are expected to be invested in hospitals.

5. Standout Statements

“We still have 50% higher revenue that we can generate from the existing facilities.”
“Most of the fresh capital will be invested in the hospital business.”
“We expect the benefit to start accruing in the P&L from Q4 of this year, with a full-quarter impact coming from Q1 FY28.”
On Mumbai: “There is no update as such on that side.”
On FOCO: “If you ask us whether we have an aggressive plan there, the answer is no.”
The CFO described the Gurgaon unit’s growth trajectory as likely to continue, while its cash break-even remains a future milestone.

6. Red Flags / Positive Signals

Red flags
– EBITDA growth lagged revenue growth; consolidated and standalone hospital margins remain below year-ago levels.
– Medtech’s positive EBITDA has not translated into strong consolidated PBT; management again withheld a detailed roadmap.
– Mumbai expansion remains delayed, with pending approvals and trustee discussions.
– Debt is lower than Q1 FY27 but remains above the Q4 FY26 reported level.
– Management’s margin recovery case relies heavily on future savings and utilization gains.

Positive signals
– Hospital occupancy rose 400 bps year on year; ALOS improved.
– Gurgaon revenue increased about 50% year on year and the unit was EBITDA-positive.
– Medtech has delivered five consecutive quarters of positive EBITDA.
– Inventory days and capex have declined materially, supporting working-capital and debt-reduction goals.
– Management said 80–90% of additional internal accruals will be directed to hospitals.

7. Historical Comparison & Consistency Analysis

Q3 FY26

Dominant tone: Neutral
Major themes this quarter:
Hospital volumes and revenue were weak; insurance business had been temporarily stopped during rate negotiations.
Doctor churn and Shalby International’s management issues were prominent.
Medtech had just reached positive EBITDA, with inventory, capacity and cost control central to the turnaround story.
Tone shift vs previous quarter: N/A (baseline)
What changed: N/A (baseline)

Q4 FY26

Dominant tone: Optimistic
Major themes this quarter:
Medtech’s EBITDA turnaround was presented as evidence of transition from investment to scale.
Hospital growth was expected from new doctors, technology, rate revisions and Gurgaon recovery.
Management emphasized lower future capex and potential debt improvement.
Tone shift vs previous quarter: More Optimistic
What changed:
Medtech moved from “breakeven” to a “scale and execute” narrative, supported by positive full-year EBITDA.
Management forecast minimum 15% long-term hospital CAGR and described substantial unused capacity.
Gurgaon EBITDA break-even was expected soon, but no firm timeline was supplied.

Q1 FY27

Dominant tone: Neutral
Major themes this quarter:
Hospital revenue improved, but standalone EBITDA margin fell sharply year on year.
Medtech revenue growth accelerated and consolidated EBITDA remained positive.
Management tied future margins to supply-chain and efficiency initiatives, doctor ramp-up and Gurgaon recovery.
Tone shift vs previous quarter: More Cautious
What changed:
The hospital margin narrative became more defensive: management called pressure temporary and cited doctor ramp-up, bunker revenue and TPA renewals.
It gave a specific FY27 hospital EBITDA-margin aspiration of “upward to 20%,” despite the current-year margin decline.
Medtech was still targeting double-digit EBITDA margins, with key initiatives expected to complete by Q4 and over the following six months.

Q2 FY27

Dominant tone: Neutral
Major themes this quarter:
Hospital growth broadened beyond orthopedics, with higher occupancy and improved Gurgaon performance.
Efficiency, utilization of existing assets and lower capex were emphasized.
Medtech’s new supply chain, gross-margin improvement and working-capital discipline became the main forward drivers.
Tone shift vs previous quarter: More Cautious
What changed:
Consolidated revenue growth held near 10%, but EBITDA was nearly flat year on year and margin fell to 14.6%.
The prior quarter’s explicit “upward to 20%” FY27 hospital-margin aspiration was not reiterated; management instead offered directional margin improvement.
Gurgaon advanced from EBITDA break-even to an expected cash break-even, while the Mumbai project remained stalled.

Trajectory Summary: The calls show a recovery in reported growth from Q3 FY26, but not a clean improvement in profitability: hospital margins weakened, and Medtech’s positive EBITDA has yet to resolve the broader profit and debt concerns. Management’s confidence remains high, but its guidance has shifted toward efficiency benefits that are still expected to arrive in later quarters.

b. Tracking Past Commitments vs Outcomes

Past statement	What was expected	Current status	Flag
Q3 FY26: Gurgaon was expected to turn EBITDA-positive within 1–2 quarters, after earlier delays attributed to management issues and doctor churn.	EBITDA break-even in the near term.	Q1 FY27 reported first-time EBITDA break-even; Q2 reported continued EBITDA positivity and expects cash break-even near Q4.	✅ Delivered, with cash break-even still pending
Q3 FY26: Hospital growth would include double-digit volume growth and 5–6% ARPOB growth in FY27.	Strong volume and realization improvement.	Q2 reported higher occupancy and ARPOB up 4.3% year on year, but did not confirm the annual volume target.	⏳ Not yet verified
Q1 FY27: Hospital EBITDA margin could reach “upward to 20%” for the full year.	FY27 margin recovery.	Q2 standalone margin was 18.2%, down 130 bps year on year; no full-year margin target was repeated.	⏳ At risk / not yet achieved
Q1 FY27: Medtech initiatives were expected to support double-digit EBITDA margins after implementation, with major changes progressing toward Q4.	Material Medtech margin expansion.	Medtech remained EBITDA-positive, but Q2 gave no double-digit margin target; supply-chain benefits are expected from Q4, with full-quarter impact in Q1 FY28.	⏳ Delayed / unproven
Q4 FY26: Capex would be substantially lower after FY26’s ₹160 crore investment.	Lower cash outflow and support for debt reduction.	H1 FY27 capex was about ₹10 crore, with similar H2 levels expected.	✅ Delivered so far
Q4 FY26 onward: Mumbai expansion was under discussion with trustees and subject to alignment.	Progress toward project confirmation.	Q2 still cited pending approvals and trustee discussions, with no update.	⏳ Delayed

c. Narrative Shifts

Hospitals: The narrative has shifted from recovering lost volumes and recruiting doctors to improving utilization, operational discipline and cost efficiency. Management now emphasizes multispecialty mix and reduced reliance on orthopedics.
Medtech: The story has moved from fixing capacity and reaching EBITDA break-even to cost-of-goods reduction, new supply chain and volume conversion. However, detailed financial targets remain absent.
Expansion: Earlier calls discussed selective franchisees and potential opportunities; management now explicitly says it is not pursuing aggressive FOCO expansion and is prioritizing existing hospitals.
Debt and investment: The emphasis is now on lower capex, cash generation and hospital-focused internal investment. Yet debt remains above the Q4 FY26 figure.

d. Consistency & Credibility Signals

Overall credibility: Medium. Management has provided measurable operating updates—Gurgaon EBITDA break-even, reduced capex, improved occupancy and lower inventory—and has acknowledged Mumbai delays and hospital underperformance. However, margin and growth aspirations have been revised or left unquantified, while several expected benefits have repeatedly been pushed into future quarters. Debt-reduction confidence also contrasts with net debt remaining above Q4 FY26.

e. Evolution of Key Themes

Hospital demand/utilization — Improving: Occupancy and Gurgaon revenue rose; mix is broadening. Some hospitals still operate below potential.
Hospital margins — Deteriorating, with recovery expected: Standalone margins are below year-ago levels; management points to future efficiencies and utilization to reverse the decline.
Medtech profitability — Improving, but not yet proven at net-profit level: Positive EBITDA has persisted, while supply-chain savings and stronger margins remain prospective.
Debt/cash conversion — Mixed: Capex and Medtech cash requirements have eased; debt declined modestly from Q1 but remains higher than Q4 FY26.
Expansion — More disciplined: Less emphasis on franchise-led growth; focus is on existing assets and limited bed additions. Mumbai remains unresolved.

f. Additional Insights

Management’s confidence in a Medtech turnaround increasingly rests on cost reductions and inventory conversion, rather than a quantified sales or EBITDA roadmap.
The hospital business is improving operationally, but higher occupancy has not yet translated into year-on-year margin expansion—a key test of the operating-leverage thesis.
Capital discipline is clearer in words and capex figures, but debt reduction has not yet become a sustained trend across the periods provided.

Shalby Revenue Rises 9.8% as EBITDA Margin Falls